Taurine and the control of basal hormone release from rat neurohypophysis.
Pituicytes of pituitary neural lobe are rich in the amino acid taurine, which they release upon hypoosmotic stimulation. As a generally inhibitory amino acid, taurine is thought to activate receptors on neural lobe nerve terminals and exert some control over hormone release. Previous work has shown the presence of glycine and GABA(A) receptors in neural lobe, both of which have affinity for taurine. Using a perifused explant system, we studied the effects of taurine activation of glycine and GABA(A) receptors on basal hormone release. Somewhat surprisingly, taurine induced increases in basal release of both vasopressin and oxytocin. Taurine-induced increases in oxytocin release were blocked by bicuculline, suggesting involvement of GABA(A) receptors. Increases in vasopressin release were not blocked by bicuculline, indicating involvement of receptors other than GABA(A). Although combined bicuculline and strychnine, an antagonist at most glycine receptors, also did not block increased vasopressin release, picrotoxin (a Cl(-) channel blocker) was effective in blocking increases in both vasopressin and oxytocin release. The other receptor(s) involved in taurine actions is postulated to be strychnine-insensitive glycine receptors. Thus, taurine in neural lobe may act via both a GABA(A) receptor and one or more types of glycine receptors to depolarize nerve terminal membranes under basal conditions. Taurine-induced partial depolarization resulting in Na(+) channel inactivation is probably responsible for its previously observed inhibition of stimulated hormone release from neural lobe.
Song
Zhilin
Z
Department of Cell Biology and Neuroscience, University of California, Riverside, CA 92521, USA.
Hatton
Glenn I
GI
D000818:Animals; D002118:Calcium / Q000378:metabolism; D018118:Chloride Channels / Q000037:antagonists & inhibitors; D018756:GABA Antagonists / Q000494:pharmacology; D005998:Glycine / Q000494:pharmacology / Q000502:physiology; D018684:Glycine Agents / Q000494:pharmacology; D066298:In Vitro Techniques; D008297:Male; D010121:Oxytocin / Q000378:metabolism; D010852:Picrotoxin / Q000494:pharmacology; D010904:Pituitary Gland, Posterior / Q000187:drug effects / Q000378:metabolism*; D010907:Pituitary Hormones / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D011963:Receptors, GABA-A / Q000187:drug effects / Q000378:metabolism; D018009:Receptors, Glycine / Q000187:drug effects / Q000378:metabolism; D013654:Taurine / Q000494:pharmacology / Q000502:physiology*; D013997:Time Factors; D014667:Vasopressins / Q000378:metabolism; D005680:gamma-Aminobutyric Acid / Q000494:pharmacology / Q000502:physiology
D002118:Calcium; D018118:Chloride Channels; D018756:GABA Antagonists; D005998:Glycine; D018684:Glycine Agents; D010121:Oxytocin; D010852:Picrotoxin; D010907:Pituitary Hormones; D011963:Receptors, GABA-A; D018009:Receptors, Glycine; D013654:Taurine; D014667:Vasopressins; D005680:gamma-Aminobutyric Acid